The role of airway mucus and diseased pulmonary epithelium on the absorption of inhaled antibodies.

In vitro lung barrier models Inhaled antibodies Lung permeability Pulmonary disposition Transwell®

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Nov 2023
Historique:
received: 14 07 2023
revised: 10 10 2023
accepted: 15 10 2023
medline: 20 11 2023
pubmed: 19 10 2023
entrez: 18 10 2023
Statut: ppublish

Résumé

Inhaled antibody therapy for the treatment of respiratory diseases is a promising strategy to maximize pulmonary exposure and reduce side effects associated with parenteral administration. However, the development of inhaled antibodies is often challenging due to a poor understanding of key mechanisms governing antibody absorption and clearance in healthy and diseased pulmonary epithelium. Here, we utilize well established Human Bronchial Epithelial Cell (HBEC) models grown at air-liquid interface to study the absorption process of antibodies and antibody fragments. With these cellular models, we recapitulate the morphology and function of healthy and diseased pulmonary epithelium, and incorporate the mucosal barrier to enable the investigation of both cellular permeability as well as mucodiffusion. We studied the saturation of antibody transport across the HBEC barriers and estimated the impact of disease-like epithelial barriers on antibody paracellular transport. Additionally, we identified a potential role of neonatal Fc receptor (FcRn)-independent and target-mediated transcytosis in the transport of Fragment antigen-binding (Fab) and F(ab)2 antibody fragments. Lastly, our models were able to pinpoint an impaired antibody diffusion across mucus gels. These mechanistic cellular models are promising in vitro tools to inform Physiologically-based Pharmacokinetic (PBPK) computational models for dose prediction toward de-risking the development of inhaled biologics.

Identifiants

pubmed: 37852310
pii: S0378-5173(23)00940-7
doi: 10.1016/j.ijpharm.2023.123519
pii:
doi:

Substances chimiques

Antibodies 0
Immunoglobulin Fragments 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123519

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest A. M. L., E. G., D. R., T. D. and W. R. T. declare to work at Novartis AG. A. M. L., E. G., D. R. and W. R. T. declare to hold stock in Novartis AG. The authors declare no other potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The Novartis Discovery Postdoctoral Fellowships provided financial support for the conduct of the research but had no role in study design, data collection, analysis and interpretation of data, writing of the report or the decision to submit the article for publication.

Auteurs

Adriana Martinez Ledo (AM)

Disease Area X, Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, United States.

Thomas Dimke (T)

Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, CH-4056 Basel, Switzerland.

William R Tschantz (WR)

NIBR Biologics Center, Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, United States.

David Rowlands (D)

Disease Area X, Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, United States.

Ellena Growcott (E)

Disease Area X, Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, United States. Electronic address: ellie.growcott@novartis.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH